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Partial hepatectomy enhances 
the growth of CC531 rat colorectal 
cancer cells both in vitro and in vivo
Borja Herrero de la Parte1,2*, Mikel González‑Arribas1, Iñaki Diaz‑Sanz1, 
Teodoro Palomares1 & Ignacio García‑Alonso1,2
Partial hepatectomy (PHx) is the gold standard for the treatment of colorectal cancer liver metastases. 
However, after removing a substantial amount of hepatic tissue, growth factors are released to 
induce liver regeneration, which may promote the proliferation of liver micrometastases or circulating 
tumour cells still present in the patient. The aim of this study is to assess the effect of PHx on the 
growth of liver metastases induced by intrasplenic cell inoculation as well as on in vitro proliferation 
of the same cancer cell line. Liver tumours were induced in 18 WAG/RijHsd male rats, by seeding 
250,000 syngeneic colorectal cancer cells (CC531) into the spleen. The left lateral lobe of the liver was 
mobilized and in half of the animals it was removed to achieve a 40% hepatectomy. Twenty‑eight days 
after tumour induction, the animals were sacrificed and the liver was removed and sliced to assess 
the relative tumour surface area (RTSA%). CC531 cells were cultured in presence of foetal calf serum, 
non‑hepatectomised (NRS) or hepatectomized rat serum (HRS), and their proliferation rate at 24, 
48, and 72 h was measured. RTSA% was significantly higher in animals which had undergone PHx 
than in the controls (non‑hepatectomised) (46.98 ± 8.76% vs. 18.73 ± 5.65%; p < 0.05). Analysing each 
lobe separately, this difference in favour of hepatectomized animals was relevant and statistically 
significant in the paramedian and caudate lobes. But in the right lobe the difference was scarce and 
not significant. In vitro, 2.5% HRS achieved stronger proliferative rates than the control cultures (10% 
FCS) or their equivalent of NRS. In this experimental model, a parallelism has been shown between 
the effect of PHx on the growth of colorectal cancer cells in the liver and the effect of the serum on 
those cells in vitro.
Colorectal cancer (CRC) is the major cause of cancer-related morbidity and mortality in developed regions. In 
the European Union (EU), it is the second leading cause of death, while in developing countries it is the  fifth1,2. 
Eurostat reports over 153,000 deaths as a result of CRC in the EU, representing 11% of cancer-associated deaths 
and 3.1% of all  deaths2,3.
Metastases are the main cause of CRC-associated morbidity and mortality. The liver is the most common 
site of metastases derived from CRC (CRCLM), due to the fact that the blood from colon and proximal parts 
of the rectum drains through the portal system to the  liver4–7. More than 50% of patients with CRC develop 
CRCLM in their  lifetime2,6, and without treatment only approximately 20 to 30% of them survive one year after 
the diagnosis of the metastatic  disease8.
Nowadays, partial hepatectomy (PHx) is the only option offering potential cure for patients with  CRCLM9,10. 
Regardless of advances in this field, less than 20% of patients are eligible for  PHx11. If performed with curative 
intent, PHx can achieve a 5-year survival rate of 23 to 51% and median survival up to 60  months11,12. Conversely, 
in untreated CRCLM patients, median survival is 3–20 months, with a 1-year survival rate of less than 30%, and 
5-year survival rate of less than 5%8.
Unfortunately, metastasis recurrence following tumour resection is quite a common  event13, most frequently 
resulting from the outgrowth of a residual disease, also called residual metastatic  disease14,15. Some studies suggest 
that these tumour microimplants or some circulating tumour cells may be in a kind of “dormant state” which is 
suddenly abandoned to begin rapid  growth16,17.
During surgical procedures, such as PHx, the disruption and rearrangement of the extracellular tumour 
matrix may promote detachment and migration of tumour cells within the remaining hepatic mass (RHM) or 
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its incorporation into the systemic circulation, which facilitates intra- or extrahepatic tumour  recurrence18. In 
addition, liver resection leads to relevant increments in the levels of growth factors (GF) and cytokines related 
with liver regeneration, which can induce changes in the microtumour implant environment. Indeed, It has been 
previously described that liver regeneration plays a significant role in tumour stimulation and metastasis, and 
that, in particular, the degree of hepatectomy appears to be a key factor for this dismal  effect19.
In fact, we have already demonstrated that PHx performed after intrasplenic inoculation of rhabdomyosar-
coma S4MH cells increases the number and size of liver implants of these tumour cells; in addition, we have 
shown that serum obtained from hepatectomized rats as well as several GFs enhance the growth of this tumour 
cell line in vitro20,21. Now, we wanted to explore whether it was something specific to this rhabdomyosarcoma 
cell line, which is known to be a very aggressive tumour, or rather something common to other tumour cell 
lines. For this reason, we have adapted our model for a syngeneic CRC cell line (CC531), in order to analyse the 
potential of hepatectomized rat serum (HRS) to enhance CC531 growth in vitro and to check the effect of 40% 
PHx on the growth of CC531 cancer cell implants in the liver.
Results
In this experiment, both in vitro and in vivo studies showed that liver resection is a strong stimulus for CC531 
cancer cell proliferation.
Effect of hepatectomized rat serum on in vitro cell proliferation. In order to select appropriate 
control conditions, first of all, we analysed the effect of adding serum obtained from normal rats (NRS) to CC531 
cell cultures, comparing their growth rate at 72 h with that of cultures enriched with conventional 10% foetal calf 
serum (FCS). Though no differences were observed during the first 48 h (Fig. 1), looking at cell counts on the 
third day, none of the cultures enriched with NRS reached the cell numbers obtained with FCS, being the culture 
with the lowest concentration of NRS (5%) the one that was closest to the control.
Then, we compared the cultures enriched with HRS with the standard 10% FCS and 5% NRS. As it had hap-
pened with NRS, none of the cultures reached the values found in control cultures (FCS). And again, the prolif-
eration rate closer to the control was seen with the lowest concentration of HRS (5%), while cultures enriched 
with higher concentrations (10% or 20%) of HRS showed significant smaller proliferative rates (Table 1).
Given these findings, we performed another set of experiments reducing the amount of rat serum added to 
the cultures (2.5%, 1%). With this lower concentrations, cultures receiving HRS achieved stronger proliferative 
rates than the control cultures (10% FCS), being 2.5% the concentration reaching the highest values (p < 0.0001) 
Figure 1.  Proliferation curve of CC531 cell cultures. Cell concentration after 24, 48 and 72 h of exposure 
to different experimental conditions. Control (10% FCS) and normal rat serum (5%, 10%, 20%). Figure and 
analysis were performed using GraphPad Prism version 6.04 for Windows, GraphPad Software, San Diego, 
California USA, www.graph pad.com.
Table 1.  Cell count after 72 h of exposure to different concentrations of rat serum. Cell count is expressed as 
media and standard deviation.
Serum concentration (v/v) Normal rat serum (cell/ml) Hepatectomized rat serum (cell/ml) p value
20% 2.84 ×  105 ± 1.12 ×  105 1.27 ×  105 ± 0.32 ×  105 < 0.0001
10% 2.95 ×  105 ± 0.93 ×  105 2.25 ×  105 ± 0.40 ×  105 < 0.0001
5% 3.22 ×  105 ± 0.82 ×  105 3.20 ×  105 ± 0.70 ×  105 n.s
2.5% 4.32 ×  105 ± 0.75 ×  105 5.18 ×  105 ± 0.38 ×  105 < 0.0001
1% 3.98 ×  105 ± 0.72 ×  105 4.34 ×  105 ± 0.33 ×  105 0.0018
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(Fig. 2). Moreover, at these low concentrations (1% and 2.5%), HRS also induced higher proliferative rates that 
their counterpart of NRS (p < 0.0001) which was not seen with greater concentrations (Fig. 3).
If we focus on the results obtained in cultures enriched with 2.5% rat serum, those cultures receiving HRS 
proliferated at quicker pace than those supplemented with NRS; the effect being statistically significant even at 
48 h (p < 0.05).
In vivo model assessment. Ultrasound examination of the animals on days 15th and 20th provided no 
useful information about tumour development, as it was not possible to accurately assess neither the size nor the 
number of tumour foci. When livers were removed on day 28th all of the animals had developed liver implants, 
regardless of whether they underwent PHx or not. Macroscopic examination of the liver showed that tumour 
foci were randomly distributed through the whole organ, without a specific pattern, though the concentration of 
tumour implants was lower in the paramedian lobe.
Effect of 40% hepatectomy on tumour development. The percentage of liver area occupied by 
tumour tissue in the group of hepatectomized animals was 2.5 times higher than in the control group (47% 
vs. 18.7%, respectively, p < 0.05; Fig. 4A; Table 2). Analysing the liver lobes separately, in the paramedian and 
caudate lobes the relative tumour surface area percentage (RTSA%) was strongly increased in hepatectomized 
animals (40.3% vs. 5.9%; 70.9 vs. 36.0%, respectively). However, in the right lateral lobe, though the percentage 
was also slightly higher in the hepatectomized group (45.4% vs. 32.7%), this difference was not big enough to be 
statistically significant (p = 0.42; Fig. 4B–D).
Figure 2.  Proliferation curves of CC531 cell cultures enriched with serum from hepatectomized rats. Control 
(10% FCS) and hepatectomized rat serum (HRS; 1%, 2.5%, 5%, 10%, 20%). Figure and analysis were performed 
using GraphPad Prism version 6.04 for Windows, GraphPad Software, San Diego, California USA, www.graph 
pad.com.
Figure 3.  Proliferation curves of CC531 cell cultures enriched with low concentration of rat serum (normal 
rat serum, NRS: white; hepatectomized rat serum, HRS: grey). Dotted line represent cell numbers of cultures 
enriched with foetal calf serum (FCS). Figure and analysis were performed using GraphPad Prism version 6.04 
for Windows, GraphPad Software, San Diego, California USA, www.graph pad.com.
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Discussion
The aim of this piece of work has been to validate an animal model in which hepatectomy clearly enhance the 
growth of tumour foci in the liver, and simultaneously assess the effect of serum obtained from hepatectomized 
animals on the proliferation rate of the same cell line. This model would be a very handy tool to test new mole-
cules with the capability of slowing tumour growth while not hindering liver regeneration. Preliminary tests could 
be carried out in vitro, and those proving to be effective could be immediately be evaluated in the in vivo model.
It could be argued that the ideal animal model to study this phenomenon would be based on naturally-appear-
ing primary CRC which subsequently develops CRCLM. Then, PHx could be performed to remove metastases, 
and the recurrence of liver metastases could be studied. However, such a model based on natural or genetic pre-
disposition to develop primary CRC and then CRCLM has several drawbacks. Major problems that discourage 
the use of such a model include: low rates of development both of primary tumours and metastases, long time 
needed for metastatic disease to become evident, a limited number of models (syngeneic and xenograft), meta-
static disease not being confined to a single location and the asynchronous development of metastatic disease, 
as well as greater associated costs of animal  housing22–24.
Chemical induction has also been accepted as an appropriate tool for tumour induction. Various compounds, 
including dimethylhydrazine and its metabolites methylnitronitrosoguanidine, N-Nitroso-N-methylurea and 
azoxymethane, are able to induce tumour and/or metastases growth in laboratory  animals25–29. These compounds 
have alkylating activity, which cause breakage of DNA chains, abnormal pairing of bases, and inhibition of cell 
division, finally, resulting in cell death. Despite these products being well known, they have several disadvantages 
when used to induce tumours. For example, long induction time, low rates of tumour development and undefined 
site of tumour development, meaning that larger numbers of animals would be required for each experimental 
group. Furthermore, as these chemical products are carcinogenic in humans, the risk of researcher exposure 
should be taken into account.
Figure 4.  Relative tumour surface area percentage (RTSA%). Bar graphs of total liver mass RTSA% (A), 
caudate lobe RTSA% (B), paramedian lobe RTSA% (C) and right lateral lobe RTSA% (D) of both control 
(non-hepatectomized animal; white) and PHx (hepatectomized animal, black) groups. Asterisk show statistical 
differences (p < 0.05). Figure and analysis were performed using GraphPad Prism version 6.04 for Windows, 
GraphPad Software, San Diego, California USA, www.graph pad.com.
Table 2.  Relative tumour surface area occupied by CRCLM in total liver mass (TL-RTSA%), caudate lobe 
(CL-RTSA%), paramedian lobe (PL-RTSA%) and right lateral lobe (RLL-RTSA%).
TL-RTSA% CL- RTSA% PL-RTSA% RLL-RTSA%
Control group 18.73 ± 5.6% 36.02 ± 12.80% 5.9 ± 1.4% 32.69 ± 10.19%
PHx group 46.98 ± 8.8% 70.91 ± 10.35% 40.33 ± 12.1% 45.38 ± 11.24%
p value 0.015 0.04 0.03 0.42
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Heterotopic implantation of cancer cells is also a validated model to induce tumour development in laboratory 
animals, particularly in rats and mice. Cells may be implanted directly into the liver parenchyma, via subcapsular 
injection, and this approach achieves a high tumour development rate (up to 60–70% of the injected animals)30–32. 
But this model is not appropriate for our purposes because it only allows the development of single well-defined 
and localized tumour implants, and also it lacks the process of tumour cell dissemination through the vascular 
tree and subsequent extravasation to produce metastatic disease in the  liver33. Another heterotopic-implantation 
method to induce CRCLM development is intrasplenic injection. Published data regarding the success rate with 
this model is, however, very heterogeneous, ranging between 20 and 100%34,35.
For this piece of work, we chose intrasplenic injection because it mimics, as closely as may be possible, the 
natural haematogenous dissemination pathway through the portal vein of CRC cells from primary colorectal 
tumours, as well as all the other natural events involved in the spreading of metastases, such as extravasation, 
implantation, extracellular matrix remodelling and CRCLM growth and development.
The immune barrier is another factor to be considered when performing tumour induction by cell injection. 
To achieve a successful model, allo- or xeno-rejection has to be avoided. This problem can be overcome by the 
use of cell lines that grow in syngeneic hosts, also called  isotransplantation36, or using immunocompromised 
host, animals which have an immune system that is suppressed or depleted and does not respond when cells 
or tissues from other species are  implanted36,37.This last approach deprives the animal of the immune system, 
which is known to be the main organizer of regenerating processes and plays a very important role in cancer.
The last important aspect concerning the model we have used is the clamping of the portal pedicle of the 
left lateral lobe (LLL). Although clamping the LLL may elicit the production of stimulating cytokines that 
could interfere with the procedure for tumour induction, the period of time that the LLL remains clamped is 
too short (5 min) to have a substantial consequence, considering the large regenerative stimulus induced by 
 hepatectomy38,39.
As the immune system plays an important role in cancer, we decided to avoid interfering with it. For this 
reason, we chose a CRC cell line (CC531) which is syngeneic to WAG/RijHsd rats. When CC531 cells are 
injected into the spleen of this strain of rats, rejection seldom  occurs40 and a high rate of success is achieved. 
In fact, in this study, we saw no cases of rejection at all, and a 100% success rate in CRCLM development. The 
fact that tumour foci were observed in every liver lobe is in consonance with the natural pattern of metastasis 
development, which reinforces our idea of it being a good experimental model for studies on liver metastases. 
Nonetheless, it is also true that this model lacks the genetic variability which is observed in human  tumours41. 
Moreover, Robertson et al. sustain that as rat liver architecture and homeostasis are quite different from those 
in humans, caution should be exercised with any extrapolation of results from this model to a clinical  setting37.
Following liver resection, a vigorous peak of HGF is found in serum, which then decreases to a plateau 
which lasts all the period of hepatocyte proliferation; the beginning of this plateau matches the first peak of 
DNA  synthesis42. To obtain rat serum rich in HGF we chose a 40% hepatectomy, because we plan to mimic 
liver surgery for metastases removing the LLL. Following a 40% hepatectomy in the rat, the first peak in DNA 
synthesis is reached after 40  h20,21,43–45, so that was the timing selected to retrieve the serum from the animals.
Our finding that there is a certain concentration of serum in the culture which elucidates the higher prolif-
erative rate of cancer cells, while values above or below show a lesser effect is in accordance with what has been 
published by other  authors45,46. Liu et al. exploring the effect of different concentrations of serum on the growth 
of mouse fibroblasts in culture, found that the highest proliferation was obtained with 20%, with higher or lower 
concentrations growth was much  lesser47.
The fact that the optimum serum concentration for the stimulation of tumour cell proliferation is lower when 
using serum from hepatectomized animals suggests that there is something in it which make it more a powerful 
stimulus for cell growth. It is well known that following any kind of surgery there is an increase in GF levels in 
serum, both in  humans48,49 and in  rats49,50. HGF increases following lung  surgery51, but the increment is quite 
greater following liver resection (from 50 to 250 ng/ml)42. To avoid inappropriate cell duplication when GF are 
produced in our organism, mammalian cells need an activator to respond to  GF50, but cancer cells lack this 
protective mechanism. These facts support the hypothesis that GF produced during surgery for CRCLM could 
be responsible of the high frequency of recurrence  reported46,52.
In fact, the experiments we have carried out in vivo have shown that 40% PHx strongly increases CRCLM 
development. Authors including Panis et al., García-Alonso et al., Krause et al. and Harun et al. have obtained 
similar results. Specifically, in an intraportal induction model of CRCLM (DHDK12 CRC cell line and syngeneic 
BDIX rats), Panis et al. demonstrated that the number of rats developing liver metastases tripled when the rats 
underwent 70% PHx (62% vs. 20%, p < 0.05)53. Working with S4MH (a rhabdomyosarcoma cell line, syngeneic 
for WAG rats) and performing 40% PHx, we reported stimulatory effects on liver metastasis development, 
compared to that observed in controls (non-hepatectomised)54. Regarding the behaviour of each liver lobe, 
our results are quite similar to this latter study. The percentage of the liver parenchyma occupied by tumour 
implants was significantly higher in the paramedian and caudate lobes in hepatectomised animals (33% vs. 24% 
and 47% vs. 17%, respectively); it was also slightly higher in the right lateral lobe, though the difference did not 
reach significance (20% vs. 17%). Krause et al., using CC531 cells and WAG rats, reported an 2.8-fold increase 
in tumour volume in their PHx group, estimated by  MRI55.
As in any other research carried out in animals, it remains to be proved that our results can be translated into 
clinical practice. There has been some recent clinical research focused on the effects of liver resection on tumour 
growth and recurrence of liver metastases. Margonis et al. have reported that those patients with a higher kinetic 
growth rate assessed in the late regeneration phase are associated with increased risk of intrahepatic recurrence. 
On the other hand, Hamm et al. in a retrospective study have found that patients with lower liver regeneration 
showed earlier recurrence of liver metastases; but they also reported that the extent of liver regeneration after 
major hepatectomy did not modify overall survival of their patients. It is our believe that beyond this apparent 
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paradox neither of the studies deny there is an effect of liver resection and surgery in general on cancer progres-
sion. If a molecule able to block the protumour effect of hepatectomy in rats were found, then the important 
translational question should have to be arisen.
In summary, the results obtained from this experimental model and our preliminary results are in accordance 
with data published by other authors, demonstrating that liver resection to remove the macroscopic metastases, 
though effective in improving short- and medium-term survival, carries the risk of promoting the proliferation 
of any tumour cells remaining in the patient. Once we have demonstrated that there is a parallelism between our 
in vivo and in vitro models, it can be used to test novel agents which could hinder the proliferative effect of liver 
resection on tumour growth while not affecting liver restoration following this surgery.
Conclusions
In our model, hepatic resection performed on tumour-bearing livers promotes both the growth of cancer cells 
in the remnant liver parenchyma and the proliferation of colorectal cancer cells in vitro. This finding supports 
the hypothesis that molecules released to the plasma after partial liver resection are responsible for cancer recur-
rence following surgical oncological treatments, and offers a useful experimental model to check new treatments.
Material and methods
All procedures involving animals were performed in strict accordance with the ARRIVE guidelines and fol-
lowed the recommendations of current national legislation on experiments involving animals or biological 
agents. All protocols were approved by the Ethics Committee on Animal Experimentation (CEEA) (ref. number: 
M20/2015/054) and Ethics Committee for Research involving Biological Agents and Genetically Modified Organ-
isms (CEIAB) (ref. number: M30/2018/022) of the University of the Basque Country (UPV/EHU).
Animals. The experiment was carried out in 24 three-month-old male WAG/RijHsd rats, weighing 270–
300 g. Animals were kept in a temperature- and humidity-controlled room with a 12-h light/dark cycle and free 
access to standard laboratory diet and water. Animals were randomly allocated to one of three groups: (1) 40% 
hepatectomy (to obtain serum for in vitro experiments; n = 6), (2) midline laparotomy and tumour inoculation 
(sham-operated group, n = 9), (3) midline laparotomy and tumour inoculation & PHx (PHx group, n = 9). All the 
surgical procedures were carried out under anaesthesia with isoflurane 1.5%.
The animals in the first group underwent 40% PHx, removing the LLL through a midline laparotomy. Forty 
hours later, they were anesthetized, had blood collected from the abdominal cava vein, and were then sacrificed. 
After centrifugation for 10 min at 3000 rpm, the serum was obtained and stored at − 20 °C until use.
All the other animals received an intrasplenic injection of 0.5 ml of 500,000 CC531 cells/ml cell suspension 
to induce liver cancer implants. A midline incision was performed to expose both the liver and the spleen. The 
LLL vascular pedicle was blocked with a Yasargil vascular microclamp, to prevent cancer cells entering this lobe 
(as such cells would be lost in animals undergoing 40% PHx). Then, the spleen was exposed and the cells were 
slowly inoculated into the organ. Once the injection had been completed, both the liver and the spleen were 
returned to the abdominal cavity and the laparotomy was closed with a running suture. Five minutes later, the 
laparotomy was reopened to excise the spleen and remove the microclamps. At this point, the LLL was exposed; in 
half of the animals, it was returned to the abdomen, while in the other half it was removed. Then, the abdominal 
wall was closed with interrupted stiches, and meloxicam (2 mg/kg) was administered. The animals were kept 
under observation until full recovery. On days 15 and 20, an ultrasound examination of the liver was performed, 
looking for any tumour foci. These examinations were carried out using a MyLab 60 Xvision system (Esaote, 
Genoa, Liguria, Italy), equipped with a multifrequency linear probe operated at 18 MHz and the focus was set 
at a depth of between 0.5 and 1.5 cm. On day 28, under isoflurane anaesthesia, the liver was removed and fixed 
in 10% formaldehyde, and the animals sacrificed.
Relative tumour surface area. Each liver lobe was identified, excised and sliced into 1 mm slices. Then, 
all slices from each lobe were photographed separately and labelled with a blinded code. Using ImageJ, (version 
1.52p for windows, U.S. National Institutes of Health, Bethesda, Maryland USA), absolute tumour surface area 
(ATSA) and absolute liver surface area (ALSA) were measured in square pixels  (p2), as shown in Fig. 5. Then, 
RTSA% was calculated [RTSA% = (ATSA/ALSA) × 100]. Once the measurements had been completed, the blind 
was broken and the data sorted by individual animal and experimental groups.
In vitro assessment of hepatectomized rat serum. To assess the potential of HRS to enhance cell 
proliferation, a series of in vitro cell proliferation studies were carried out. CC531 cells were incubated at 37 ºC 
and 5%  CO2 in RPMI-based culture medium supplemented with 10% (v/v) foetal calf serum (FCS), antibiotics 
(100 IU/ml penicillin and 100 µg/ml streptomycin) and antimycotics (0.25 µg/ml amphotericin B). Once the 
culture reached semi-confluence, the cells were harvested and seeded on 24-multiwell culture plates at 30,000 
cells/ml. The control wells were supplemented with 10% FCS, while those of experimental groups were supple-
mented with either 5, 10 or 20% NRS (obtained from non-hepatectomized rats) or 1, 2.5, 5, 10, or 20% HRS. Cell 
proliferation was assessed using NucleoCounter NC-100 (Chemometec, Allerod, Denmark) and xCELLIgence 
RTCA SP (ACEA Biosciences Inc. San Diego, California, USA).
Statistical analysis. The normality of the data was checked with the Kolmogorov–Smirnov test, and results 
were summarized using means and standard deviations. Comparisons between two groups were carried out 
using two-tailed t-tests with a confidence level of 95% (for in vivo studies). When three or more groups were 
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compared (for in vitro studies), an analysis of variance (ANOVA) was performed, and Newman–Keuls multiple 
comparison test for between-group comparison was performed when ANOVA showed significant differences 
(p < 0.05). Statistical analyses were performed using GraphPad Prism version 6.04 for Windows, GraphPad Soft-
ware, San Diego, California USA.
Ethics approval and consent to participate. This project has been approved by the Ethics Committee 
on Animal Experimentation (CEEA) (ref. number: M20/2015/054) and Ethics Committee for Research involv-
ing Biological Agents and Genetically Modified Organisms (CEIAB) (ref. number: M30/2018/022) of the Uni-
versity of the Basque Country (UPV/EHU).
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